Not provided
Not provided
Not provided
Not provided
Not provided
Lack of enrollement
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| UCB Pharma | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Trial to determine if seizure prophylaxis with IV LCM in NSICU patients experiencing mental status changes due to severe traumatic brain injury (sTBI) will result in improved short- and long-term outcomes and better immediate adverse effects when compared to the current standard of care anticonvulsant (IV fPHT) and will be at least as effective as IV fPHT in preventing clinical and sub-clinical seizure activity.
The goals are to compare IV LCM and IV fPHT for seizure prophylaxis in the neuro-critical care setting in terms of the following outcome measures:
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| IV LCM (lacosamide) | Experimental | Patients with severe traumatic brain injury (TBI) or subarachanoid hemorrhage (SAH) randomized to seizure prophylaxis with either lacosamide. |
|
| IV fPHT (fos-phenytoin) | Active Comparator | Patients with TBI or SAH randomized to seizure prophylaxis with fos-phenytoin |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| lacosamide | Drug | 200 mg IV over 60 minutes; these patients will then be started on a maintenance dose 100 mg, IV BID as prophylaxis administered as per pharmacy protocol consistent with acceptable standards of care for 7 days. The Lacosamide dose can be adjusted as needed if seizures occur for therapeutic effect up to 200 mg bid (400 mg/d) as a maximum dose. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Adverse Events | The primary outcome measure is the incidence of clinical adverse events. These will be followed by daily clinical observations during the hospital stay. Subjects will be evaluated for e.g., seizures, fever, neurological changes, cardiovascular, hematologic and dermatologic abnormalities, liver failure, renal failure, and death; EKGs will be requested as per ICU routines through day 7. | baseline to 7 days |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Seizures | Number of seizures in the first 72 hours based on EEG recording | baseline to 72 hours |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jerzy P Szaflarski, M.D., PhD | Univeristy of Cincinnati | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UC Health University Pointe | Cincinnati | Ohio | 45069 | United States | ||
| UC Health Medical Arts Building |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 19898966 | Background | Szaflarski JP, Sangha KS, Lindsell CJ, Shutter LA. Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. Neurocrit Care. 2010 Apr;12(2):165-72. doi: 10.1007/s12028-009-9304-y. |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | IV LCM | Patients with severe TBI later randomized to seizure prophylaxis with LCM (Lacosamide). For IV LCM dosing and adjustment see "Intervention" section. |
| FG001 | IV fPHT | Patients randomized to fPHT (fos-phenytoin) with moderate or severe TBI. For IV fPHT dosing and adjustment see "Intervention" section. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Traumatic Brain Injury
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | IV LCM | patients randomized to IV LCM (7) |
| BG001 | IV fPHT | patients randomized to IV fPHT (4) |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Median |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Adverse Events | The primary outcome measure is the incidence of clinical adverse events. These will be followed by daily clinical observations during the hospital stay. Subjects will be evaluated for e.g., seizures, fever, neurological changes, cardiovascular, hematologic and dermatologic abnormalities, liver failure, renal failure, and death; EKGs will be requested as per ICU routines through day 7. | all participants in each arm were available for analyses | Posted | Number | number of events experienced | baseline to 7 days |
|
baseline to 7 days
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | IV LCM | Patients with severe TBI later randomized to seizure prophylaxis with lacosamide. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| death | Nervous system disorders | Systematic Assessment | death because of baseline condition (TBI) - expected |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| fever | Investigations | Systematic Assessment |
Early termination due to lack of enrollment. Statistical comparisons between groups are not possible and were not performed.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Jerzy P. Szaflarski, MD | University of Alabama at Birmingham | 205-934-3866 | szaflaj@uab.edu |
Not provided
| ID | Term |
|---|---|
| D000070642 | Brain Injuries, Traumatic |
| D012640 | Seizures |
| ID | Term |
|---|---|
| D001930 | Brain Injuries |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000078334 | Lacosamide |
| C043114 | fosphenytoin |
| D010672 | Phenytoin |
| ID | Term |
|---|---|
| D000081 | Acetamides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D000085 | Acetates |
| D000144 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Fosphenytoin | Drug | 20 mgPE/kg IV over 60 minutes and then will be started on a maintenance dose (5 mgPE/kg/day, rounded to nearest dose of 150 mgPE IV, BID administered as per pharmacy protocol consistent with acceptable standards of care for 7 days |
|
|
| Cincinnati |
| Ohio |
| 45219 |
| United States |
| University Hospital | Cincinnati | Ohio | 45219 | United States |
| BG002 |
| Total |
Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
Patients with severe TBI randomized to seizure prophylaxis with fPHT
|
|
| Secondary | Number of Participants With Seizures | Number of seizures in the first 72 hours based on EEG recording | Posted | Number | number of participants with seizures | baseline to 72 hours |
|
|
|
| 2 |
| 7 |
| 7 |
| 7 |
| EG001 | IV fPHT | Patients with severe TBI later randomized to seizure prophylaxis with phenytoin. | 0 | 4 | 4 | 4 |
|
| increased ICP | Nervous system disorders | Systematic Assessment |
|
| Hypotension | Investigations | Systematic Assessment |
|
| LFT | Hepatobiliary disorders | Systematic Assessment |
|
| stroke | Nervous system disorders | Systematic Assessment |
|
| arrythmia | Cardiac disorders | Systematic Assessment |
|
| anemia | Blood and lymphatic system disorders | Systematic Assessment |
|
| low platelets | Blood and lymphatic system disorders | Systematic Assessment |
|
| skin reaction | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
Not provided
Not provided
| D006259 |
| Craniocerebral Trauma |
| D020196 | Trauma, Nervous System |
| D014947 | Wounds and Injuries |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| Acids, Acyclic |
| D002264 | Carboxylic Acids |
| D006827 | Hydantoins |
| D048289 | Imidazolidines |
| D007093 | Imidazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |